Humabs BioMed
Bellinzona, Switzerland
Purpose
to fund the discovery, characterization and selection of human monoclonal IgA antibodies with pre-clinical efficacy against three enteric pathogens responsible for life-threating diarrhea in neonates
Division
Global Health
Date
April 2017
Region Served
GLOBAL
Committed amount
$4,549,751
Grant topic
Create Novel Technology Platform Capabilities
Duration (months)
26
Grantee location
Bellinzona, Switzerland
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.